NFKB1 and systemic lupus erythematosus: Leukadherin-1 has also been shown to restrict the activation of the NF-κB and proinflammatory cytokine synthesis pathways, rescuing the MRL/MpJ-Faslpr lupus model from skin and renal pathology (47), supporting further exploration of CD11b agonism as a therapeutic approach for lupus and other nephritic diseases.